Raj joined Advent in 2005 bringing over 20 years of experience in biomedical research and as an entrepreneur and investor.
After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics.
Since joining Advent, Raj has been mainly involved in founding and supporting our portfolio Companies that are involved in the discovery of new medicines. Raj currently serves on the Board of several portfolio Companies including Arrakis, Aura BioSciences, Levicept and Rappta Therapeutics.
Raj currently serves on the Board of several portfolio Companies including Arrakis, Aura Biosciences and Levicept.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.